Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model

Valentina K. Todorova, Eric R. Siegel, Yihong Kaufmann, Asangi Kumarapeli, Aaron Owen, Jeanne Y. Wei, Issam Makhoul, V. Suzanne Klimberg

Research output: Contribution to journalArticle

Abstract

Dysregulation of calcium homeostasis is a major mechanism of doxorubicin (DOX)-induced cardiotoxicity. Treatment with DOX causes activation of sarcoplasmic reticulum (SR) ryanodine receptor (RYR) and rapid release of Ca2+ in the cytoplasm resulting in depression of myocardial function. The aim of this study was to examine the effect of dantrolene (DNT) a RYR blocker on both the cardiotoxicity and antitumor activity of DOX in a rat model of breast cancer. Female F344 rats with implanted MAT B III breast cancer cells were randomized to receive intraperitoneal DOX twice per week (12 mg/kg total dose), 5 mg/kg/day oral DNT or a combination of DOX + DNT for 3 weeks. Echocardiography and blood troponin I levels were used to measure myocardial injury. Hearts and tumors were evaluated for histopathological alterations. Blood glutathione was assessed as a measure of oxidative stress. The results showed that DNT improved DOX-induced alterations in the echocardiographic parameters by 50%. Histopathologic analysis of hearts showed reduced DOX induced cardiotoxicity in the group treated with DOX + DNT as shown by reduced interstitial edema, cytoplasmic vacuolization, and myofibrillar disruption, compared with DOX-only–treated hearts. Rats treated with DNT lost less body weight, had higher blood GSH levels and lower troponin I levels than DOX-treated rats. These data indicate that DNT is able to provide protection against DOX cardiotoxicity without reducing its antitumor activity. Further studies are needed to determine the optimal dosing of DNT and DOX in a tumor-bearing host.

Original languageEnglish (US)
Pages (from-to)471-480
Number of pages10
JournalTranslational Oncology
Volume13
Issue number2
DOIs
StatePublished - Feb 2020

Fingerprint

Dantrolene
Doxorubicin
Breast Neoplasms
Ryanodine Receptor Calcium Release Channel
Troponin I
Cardiotoxicity
Heart Neoplasms
Inbred F344 Rats
Sarcoplasmic Reticulum
Glutathione
Echocardiography
Edema
Cytoplasm

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model. / Todorova, Valentina K.; Siegel, Eric R.; Kaufmann, Yihong; Kumarapeli, Asangi; Owen, Aaron; Wei, Jeanne Y.; Makhoul, Issam; Klimberg, V. Suzanne.

In: Translational Oncology, Vol. 13, No. 2, 02.2020, p. 471-480.

Research output: Contribution to journalArticle

Todorova, Valentina K. ; Siegel, Eric R. ; Kaufmann, Yihong ; Kumarapeli, Asangi ; Owen, Aaron ; Wei, Jeanne Y. ; Makhoul, Issam ; Klimberg, V. Suzanne. / Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model. In: Translational Oncology. 2020 ; Vol. 13, No. 2. pp. 471-480.
@article{3ff5a8e3ad52464f96fc296e442d4b56,
title = "Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model",
abstract = "Dysregulation of calcium homeostasis is a major mechanism of doxorubicin (DOX)-induced cardiotoxicity. Treatment with DOX causes activation of sarcoplasmic reticulum (SR) ryanodine receptor (RYR) and rapid release of Ca2+ in the cytoplasm resulting in depression of myocardial function. The aim of this study was to examine the effect of dantrolene (DNT) a RYR blocker on both the cardiotoxicity and antitumor activity of DOX in a rat model of breast cancer. Female F344 rats with implanted MAT B III breast cancer cells were randomized to receive intraperitoneal DOX twice per week (12 mg/kg total dose), 5 mg/kg/day oral DNT or a combination of DOX + DNT for 3 weeks. Echocardiography and blood troponin I levels were used to measure myocardial injury. Hearts and tumors were evaluated for histopathological alterations. Blood glutathione was assessed as a measure of oxidative stress. The results showed that DNT improved DOX-induced alterations in the echocardiographic parameters by 50{\%}. Histopathologic analysis of hearts showed reduced DOX induced cardiotoxicity in the group treated with DOX + DNT as shown by reduced interstitial edema, cytoplasmic vacuolization, and myofibrillar disruption, compared with DOX-only–treated hearts. Rats treated with DNT lost less body weight, had higher blood GSH levels and lower troponin I levels than DOX-treated rats. These data indicate that DNT is able to provide protection against DOX cardiotoxicity without reducing its antitumor activity. Further studies are needed to determine the optimal dosing of DNT and DOX in a tumor-bearing host.",
author = "Todorova, {Valentina K.} and Siegel, {Eric R.} and Yihong Kaufmann and Asangi Kumarapeli and Aaron Owen and Wei, {Jeanne Y.} and Issam Makhoul and Klimberg, {V. Suzanne}",
year = "2020",
month = "2",
doi = "10.1016/j.tranon.2019.12.006",
language = "English (US)",
volume = "13",
pages = "471--480",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "2",

}

TY - JOUR

T1 - Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model

AU - Todorova, Valentina K.

AU - Siegel, Eric R.

AU - Kaufmann, Yihong

AU - Kumarapeli, Asangi

AU - Owen, Aaron

AU - Wei, Jeanne Y.

AU - Makhoul, Issam

AU - Klimberg, V. Suzanne

PY - 2020/2

Y1 - 2020/2

N2 - Dysregulation of calcium homeostasis is a major mechanism of doxorubicin (DOX)-induced cardiotoxicity. Treatment with DOX causes activation of sarcoplasmic reticulum (SR) ryanodine receptor (RYR) and rapid release of Ca2+ in the cytoplasm resulting in depression of myocardial function. The aim of this study was to examine the effect of dantrolene (DNT) a RYR blocker on both the cardiotoxicity and antitumor activity of DOX in a rat model of breast cancer. Female F344 rats with implanted MAT B III breast cancer cells were randomized to receive intraperitoneal DOX twice per week (12 mg/kg total dose), 5 mg/kg/day oral DNT or a combination of DOX + DNT for 3 weeks. Echocardiography and blood troponin I levels were used to measure myocardial injury. Hearts and tumors were evaluated for histopathological alterations. Blood glutathione was assessed as a measure of oxidative stress. The results showed that DNT improved DOX-induced alterations in the echocardiographic parameters by 50%. Histopathologic analysis of hearts showed reduced DOX induced cardiotoxicity in the group treated with DOX + DNT as shown by reduced interstitial edema, cytoplasmic vacuolization, and myofibrillar disruption, compared with DOX-only–treated hearts. Rats treated with DNT lost less body weight, had higher blood GSH levels and lower troponin I levels than DOX-treated rats. These data indicate that DNT is able to provide protection against DOX cardiotoxicity without reducing its antitumor activity. Further studies are needed to determine the optimal dosing of DNT and DOX in a tumor-bearing host.

AB - Dysregulation of calcium homeostasis is a major mechanism of doxorubicin (DOX)-induced cardiotoxicity. Treatment with DOX causes activation of sarcoplasmic reticulum (SR) ryanodine receptor (RYR) and rapid release of Ca2+ in the cytoplasm resulting in depression of myocardial function. The aim of this study was to examine the effect of dantrolene (DNT) a RYR blocker on both the cardiotoxicity and antitumor activity of DOX in a rat model of breast cancer. Female F344 rats with implanted MAT B III breast cancer cells were randomized to receive intraperitoneal DOX twice per week (12 mg/kg total dose), 5 mg/kg/day oral DNT or a combination of DOX + DNT for 3 weeks. Echocardiography and blood troponin I levels were used to measure myocardial injury. Hearts and tumors were evaluated for histopathological alterations. Blood glutathione was assessed as a measure of oxidative stress. The results showed that DNT improved DOX-induced alterations in the echocardiographic parameters by 50%. Histopathologic analysis of hearts showed reduced DOX induced cardiotoxicity in the group treated with DOX + DNT as shown by reduced interstitial edema, cytoplasmic vacuolization, and myofibrillar disruption, compared with DOX-only–treated hearts. Rats treated with DNT lost less body weight, had higher blood GSH levels and lower troponin I levels than DOX-treated rats. These data indicate that DNT is able to provide protection against DOX cardiotoxicity without reducing its antitumor activity. Further studies are needed to determine the optimal dosing of DNT and DOX in a tumor-bearing host.

UR - http://www.scopus.com/inward/record.url?scp=85077445862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077445862&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2019.12.006

DO - 10.1016/j.tranon.2019.12.006

M3 - Article

AN - SCOPUS:85077445862

VL - 13

SP - 471

EP - 480

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 2

ER -